FIG 4.

IFN-α14 suppression of established HIV-1 infection. (A) The in vivo experimental design consisted of intraperitoneal infection of TKO-BLT mice with 10⁴ TCIU of HIV-1_JR-CSF, followed by 5 weeks of infection. At 35 dpi, plasma p24 levels were determined and the mice were assigned to similarly infected treatment groups for intravenous (IV) administration of IFN-α2, IFN-α14, or mock saline. Treatment was administered daily for 10 consecutive days, followed by sample collection 24 h after the final injection (45 dpi). (B) Levels of HIV-1 antigenemia as determined by p24 ELISA at the start (35 dpi) and 24 h after the final IFN injection (45 dpi). The percent reduction in plasma p24 was used to determine significance by one-way ANOVA with Tukey's posttest. (C) HIV-1 RNA copies per milliliter of plasma at 45 dpi, detected by qPCR. (D) HIV-1 proviral copies detected in CD4 cell-enriched TKO-BLT splenocytes at 45 dpi. The horizontal lines denote means. Statistical analyses were done by one-way ANOVA with Tukey's posttest. ns, not significant; ***, P < 0.001; **, P < 0.01; *, P < 0.05. Each dot represents a separate mouse.